This program centers on the work of Dr. Pnina Brodt from the Research Institute of the McGill University Hospital Center. Dr. Brodt demonstrated that a soluble decoy receptor for Insulin Growth Factor-1 (IGF-1) can act as a trap for the ligand, and an Fc-fusion thereof both achieved efficacy in animal models of breast, colon and lung cancer. This program focuses on the validation of the optimized Fc-fusion Trap of IGF-1 with an improved pharmacokinetic profile and IGF1/2 binding properties by testing it in an animal model of triple-negative breast cancer.